Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

TORONTO, July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and twelve months ended May 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars.

2008 HIGHLIGHTS

- Initiation of GLP toxicology studies for Lorus' lead anticancer small

molecule drug LOR-253. The toxicology studies, currently underway,

are designed to support the filing of an Investigational New Drug

(IND) application with the U.S. FDA for LOR-253 to initiate a Phase I

clinical study in cancer indications. Lorus intends to submit an IND

for LOR-253 by the Q4/2008 or 1Q/2009, following successful

completion of the toxicology program in the third quarter of 2008

calendar year.

- Announced completion of a proof-of-concept clinical trial in Acute

Myeloid Leukemia (AML), and expansion of its LOR-2040 development

program in this indication, with initiation of a more advanced

Phase II clinical trial. The proof-of-concept study generated

encouraging results demonstrating safety and appropriate dosing of

the combination regimen. Notably, promising clinical responses in

patients under 60 years of age were obtained which included complete

responses in 35% of the 23 patients and significant cytoreduction of

leukemic blasts in two others. Moreover, the clinical responses

correlated with downregulation of R2, the cellular target of LOR-

2040, and were further supported by demonstration of intracellular

LOR-2040 in circulating and bone marrow leukemic cells.

- Signed an exclusive multinational license agreement with Zor

Pharmaceuticals LLC ("ZOR") formed as a subs
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Slone ... Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, reported ... positions at the director level and above from July ... to stay on top of rapid breakthroughs in diagnostics, ... many diagnostic companies have been forced to fold, consolidate, ...
(Date:10/1/2014)... The U.S. Department of Labor has awarded ... as part of the Trade Adjustment Assistance Community College ... by the Department of Labor and Department of Education. ... E. Perez and Secretary of Education Arne Duncan announced ... to nearly 270 colleges across the country. , ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... 2011 Debiopharm Group™ (Debiopharm), a ... drug development and companion diagnostics, will present tomorrow ... Professor Stefano Piccolo as well as two inaugural ... Professor Etienne Meylan and Doctor Volker Busskamp. The ...
... of the INRS,s Energy, Materials, and Telecommunications Centre, has ... Medal in Chemistry. Granted by the Royal Society of ... major breakthroughs in the fields of molecular self-assembly and ... Dr. Rosei has held the Canada Research ...
... 7, 2011 CMC Biologics and Oxford BioTherapeutics (OBT) ... license agreement providing OBT with access to CMC Biologics, ... have not been disclosed, covers the research, development, and ... CHEF1 cell line development platform promotes high level expression ...
Cached Biology Technology:Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium 2Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
(Date:9/29/2014)... a NASA story from 2009, "human activities in this area ... issue. Palm oil is increasingly grown for use as a ... processed foods. It has become the most widely produced edible ... years to surpass that of soybean oil. , The environmental ... be cleared to grow the crop, and the preferred method ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... Bacteria can directly cause human blood and plasma to ... lost during the course of vertebrate evolution, according to ... of Allergy and Infectious Diseases, and Institut Pasteur in ... in Nature Chemical Biology . , The discovery ...
... designing and manufacturing biomedical sensors, healthcare and its related ... learn what to expect from this new and growing ... seminar set for Nov. 6, 2008, from 4:45-6 p.m., ... (ECE) Building, 141 Warren St, at the northwest corner ...
... in Italy have found bacteria in the root of ... the cosmetic and perfumery industries. These bacteria seem to ... change the molecular structure of the oil, giving it ... Studying the root of the tropical Vetiver grass ...
Cached Biology News:Nature study demonstrates that bacterial clotting depends on clustering 2NJIT seminar set for Nov. 6 to focus on bioelectronics -- emerging research area 2Bacteria manage perfume oil production from grass 2
... The MBS Satellite Thermal ... and flexible solution for medium ... The MBS combines the latest ... friendly software and PC control, ...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
Glycerokinase; from Bacillus stearothermophilus...
...
Biology Products: